Bioreductive Drugs: from Concept to Clinic

Clinical Oncology

Volumn 19, Issue 6, 2007, Pages 427-442

  McKeown, S R ^a   Cowen, R L ^b   Williams, K J ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive drugs; clinical studies; pre clinical studies; review; tumour hypoxia

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 3 AMINO 1,2,4 BENZOTRIAZINE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALIPHATIC COMPOUND; ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; BIOREDUCTIVE AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 REDUCTASE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INDUCIBLE NITRIC OXIDE SYNTHASE; MELPHALAN; MITOMYCIN C; NLCQ 1; PACLITAXEL; PORFIROMYCIN; PR 104; QUINONE DERIVATIVE; RADIOSENSITIZING AGENT; THIOTEPA; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CELL HYPOXIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; RADIATION RESPONSE; RESPIRATORY DISTRESS; SKIN DISCOLORATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA; VOMITING;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; GENE THERAPY; HUMANS; MITOMYCIN; NEOPLASMS; POLYCYCLIC HYDROCARBONS, AROMATIC; QUINONES; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 34347263760     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.03.006     Document Type: Article

References (181)

1. Gray L.H., Conger A.D., Ebert M., Hornsey S., and Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
2. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9 (1955) 539-549
3. Hall E.J., and Giaccia A.J. Radiobiology for the radiologist. 6th edn (2005), Lippincott, Wilkins & Watkins, Philadelphia
4. Lin A.J., Cosby L.A., Shansky C.W., and Sartorelli A.C. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J Med Chem 15 (1973) 1247-1252
5. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 60 (2002) 634-639
6. Le Q.T., Kovacs M.S., Dorie M.J., et al. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 5 (2003) 375-383
7. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
8. In: Vaupel P., and Kelleher D.K. (Eds). Tumour hypoxia: pathophysiology, clinical significance and therapeutic perspectives (1999), Wissenschaftliche Verlagsgesellschaft, Stuttgart
9. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14 (1988) 831-838
10. Okunieff P., Hockel M., Dunphy E.P., Schlenger K., Knoop C., and Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumours treated with radiation alone. Int J Radiat Oncol Biol Phys 26 (1993) 631-636
11. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumour oxygenation predicts for the likelihood of distant metastasis in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
12. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
13. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response in patients with cervix cancer. Radiother Oncol 48 (1998) 49-156
14. Nordsmark M., and Overgaard J. A confirmatory prognostic study on oxygenation status and regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57 (2000) 39-43
15. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
16. Webster L., Hodgkiss R.J., and Wilson G.D. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br J Cancer 77 (1998) 227-234
17. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
18. Young S.D., Marshall R.S., and Hill R.P. Hypoxia induces DNA over-replication and enhances metastatic potential of murine tumour cells. Proc Natl Acad Sci USA 85 (1988) 9533-9537
19. Reynolds T.Y., Rockwell S., and Glazer P.M. Genetic instability induced by the tumour microenvironment. Cancer Res 56 (1996) 5754-5757
20. Hill R.P. Tumour progression: potential role of unstable genomic changes. Cancer Metas Rev 9 (1990) 137-147
21. Teicher B.A. Hypoxia and drug resistance. Cancer Metas Rev 13 (1994) 139-168
22. Bindra R.S., Schaffer P.J., Meng A., et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24 (2004) 8504-8518
23. Koshiji M., To K.K., Hammer S., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 17 (2005) 793-803
24. Maxwell P.H. Hypoxia-inducible factor as a physiological regulator. Exp Physiol 90 (2005) 791-797
25. Semenza G.L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 19 (2004) 176-182
26. Krishnamachary B., Berg-Dixon S., Kelly B., et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63 (2003) 1138-1143
27. Erler J.T., Bennewith K.L., Nicolau M., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
28. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
29. Williams K.J., Cowen R.L., Brown L.M., Chinje E.C., Jaffar M., and Stratford I.J. Hypoxia in tumors: molecular targets for anti-cancer therapeutics. Adv Enzyme Regul 44 (2004) 93-108
30. Moeller B.J., Dreher M.R., Rabbani Z.N., et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
31. Williams K.J., Telfer B.A., Xenaki D., et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75 (2005) 89-98
32. Brown L.M., Cowen R.L., Debray C., et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69 (2006) 411-418
33. Unruh A., Ressel A., Mohamed H.G., et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 22 (2003) 3213-3220
34. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
35. Bos R., Zhong H., Hanrahan C.F., et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93 (2001) 309-314
36. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., and Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavourable prognosis in early-stage invasive cervical cancer. Cancer Res 60 (2000) 4693-4696
37. Birner P., Schindl M., Obermair A., Breitenecker G., and Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
38. Bachtiary B., Schindl M., Potter R., et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9 (2003) 2234-2240
39. Hutchison G.J., Valentine H.R., Loncaster J.A., et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 10 (2004) 8405-8412
40. Airley R., Loncaster J., Davidson S., et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7 (2001) 928-934
41. Loncaster J.A., Harris A.L., Davidson S.E., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61 (2001) 6394-6399
42. Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., and Lee W.W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12 (1986) 1239-1242
43. Patterson A.V., Barham H.M., Chinje E.C., Adams G.E., Harris A.L., and Stratford I.J. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72 (1995) 1144-1150
44. Patterson A.V., Saunders M.P., Chinje E.C., Talbot D.C., Harris A.L., and Strafford I.J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76 (1997) 1338-1347
45. Patterson A.V., Saunders M.P., Chinje E.C., Patterson L.H., and Stratford I.J. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des 13 (1998) 541-573
46. Saunders M.P., Patterson A.V., Chinje E.C., Harris A.L., and Stratford I.J. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 82 (2000) 651-656
47. Fitzsimmons S.A., Lewis A.D., Riley R.J., and Workman P. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15 (1994) 1503-1510
48. Garner A.P., Paine M.J.I., Rodriguez-Crespo I., et al. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 59 (1999) 1929-1934
49. Chinje E.C., Cowen R.L., Feng J., et al. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 63 (2003) 1248-1255
50. Robertson N., Haigh A., Adams G.E., and Stratford I.J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A (1994) 1013-1019
51. Saunders M.P., Jaffar M., Patterson A.V., et al. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 59 (2000) 993-996
52. Bailey S.M., Lewis A.D., Patterson L.H., Fisher G.R., Knox R.J., and Workman P. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol 62 (2001) 461-468
53. Cowen R.L., Patterson A.V., Telfer B.A., et al. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol Cancer Ther 2 (2003) 901-909
54. Jaffar M., Williams K.J., and Stratford I.J. Bioreductive and gene therapy approaches to hypoxic diseases. Adv Drug Deliv Rev 53 (2001) 217-228
55. Kim J.Y., Patterson A.V., Stratford I.J., and Hendry J.H. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines. Anticancer Drugs 15 (2004) 71-77
56. Walton M.I., Sugget N., and Workman P. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 22 (1992) 643-647
57. Gan Y., Mo Y., Kalns J.E., et al. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res 7 (2001) 1313-1319
58. Patterson L.H., McKeown S.R., Robson T., Gallagher R., Raleigh S.M., and Orr S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Des 14 (1999) 473-486
59. Raleigh S.M., Wanogho E., Burke M.D., McKeown S.R., and Patterson L.H. Involvement of human cytochrome P450(CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys 42 (1998) 763-767
60. Chinje E.C., Kong Z., Williams K.J., Telfer B.A., Wind N.S., and Stratford I.J. Elevated human NOS II activity in HT1080 fibrosarcoma tumor cells enhances AQ4N reductive metabolism in vitro. Proc AACR 45 (2004) 564
61. Papadopoulou M.V., Ji M., Rao M.K., and Bloomer W.D. Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 14 (2003) 21-29
62. Papadopoulou M.V., and Bloomer W.D. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 9 (2003) 5714-5720
63. Wilson W.R., Pullen S.M., Degenkolbe A., et al. Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins. Eur J Cancer Suppl. 2 (2004) 151
64. Kennedy K.A., Teicher B.A., Rockwell S., and Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 29 (1980) 1-8
65. Rockwell S. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 38 (1986) 229-235
66. Stratford I.J., and Stephens M.A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 16 (1989) 973-976
67. Traver R.D., Horikoshi T., Danenberg K.D., et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52 (1992) 797-802
68. Malkinson A.M., Siegel D., Forrest G.L., et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res 52 (1992) 4752-4757
69. Smitskamp-Wilms E., Giaccone G., Pinedo H.M., van der Laan B.F., and Peters G.J. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?. Br J Cancer 72 (1995) 917-921
70. Marin A., Lopez de Cerain A., Hamilton E., et al. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 76 (1997) 923-929
71. Li D., Gan Y., Wientjes M.G., Badalament R.A., and Au J.L. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors. J Urol 166 (2001) 2500-2505
72. Nishiyama M., Saeki S., Aogi K., Hirabayashi N., and Toge T. Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells: differences in in vitro and in vivo systems. Int J Cancer 53 (1993) 1013-1016
73. Phillips R.M., Burger A.M., Loadman P.M., Jarrett C.M., Swaine D.J., and Fiebig H.H. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development. Cancer Res 60 (2000) 6384-6390
74. Fracasso P.M., and Sartorelli A.C. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res 46 (1986) 3939-3944
75. Belcourt M.F., Hodnick W.F., Rockwell S., and Sartorelli A.C. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc Natl Acad Sci USA 93 (1996) 456-460
76. Keyes S.R., Rockwell S., and Sartorelli A.C. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells. Cancer Res 47 (1987) 5654-5657
77. Rockwell S., Keyes S.R., and Sartorelli A.C. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res 116 (1988) 100-113
78. Plumb J.A., Gerritsen M., Milroy R., Thomson P., and Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys 29 (1994) 295-299
79. Plumb J.A., and Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56 (1994) 134-139
80. Stratford I.J., Williams K.J., Cowen R.L., and Jaffar M. Combining bioreductive drugs and radiation for the treatment of solid tumours. Semin Radiat Oncol 13 (2003) 42-52
81. Hall E.J., and Roizin-Towle L. Hypoxic sensitizers: radiobiological studies at the cellular level. Radiology 117 (1975) 453-457
82. Moore B.A., Palcic B., and Skarsgard L.D. Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammalian cells. Radiat Res 67 (1976) 459-473
83. Taylor Y.C., and Rauth A.M. Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro. Br J Cancer 41 (1980) 892-900
84. Sutherland R.M., Keng P., Conroy P.J., McDermott D., Bareham B.J., and Passalacqua W. In vitro hypoxic cytotoxicity of nitroimidazoles: uptake and cell cycle phase specificity. Int J Radiat Oncol Biol Phys 8 (1982) 745-748
85. Overgaard J., and Horsman M.R. Overcoming hypoxic cell radioresistance. In: Steel G.G. (Ed). Basic clinical radiobiology. 2nd edn (1997), Arnold Press, London
86. Stratford I.J., O'Neill P., Sheldon P.W., Silver A.R., Walling J.M., and Adams G.E. RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 35 (1986) 105-109
87. Stratford I.J., Adams G.E., Godden J., and Howells N. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol 55 (1989) 411-422
88. Horwich A., Holliday S.B., Deacon J.M., and Peckham M.J. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069. Br J Radiol 59 (1986) 1238-1240
89. Breider M.A., Pilcher G.D., Graziano M.J., and Gough A.W. Retinal degeneration in rats induced by Cl-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol 26 (1998) 234-239
90. Papadopoulou M.V., Ji M., Rao M.K., and Bloomer W.D. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12 (2000) 185-192
91. Papadopoulou M.V., Bloomer W.D., and Hollingshead M.G. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts. Anticancer Res 25 (2005) 1865-1869
92. Papadopoulou M.V., Ji M., and Bloomer W.D. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 48 (2001) 160-168
93. Papadopoulou M.V., Ji M., Rao M.K., and Bloomer W.D. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine. Oncol Res 12 (2001) 325-333
94. Papadopoulou M.V., Ji M., Ji X., and Bloomer W.D. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine. Cancer Chemother Pharmacol 50 (2002) 291-298
95. Papadopoulou M.V., Ji M., and Bloomer W.D. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine. Oncol Res 13 (2002) 47-54
96. Papadopoulou M.V., Ji X., and Bloomer W.D. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo. J Exp Ther Oncol 5 (2006) 261-272
97. Denny W.A. The design of drugs that target tumour hypoxia. Aust J Chem 57 (2004) 821-828
98. Cobb L.M., Connors T.A., Elson L.A., et al. 2,4-Dinitro-5-ethyeneimino-benzamide (CB1954): a potent and selective inhibitor of growth of the Walker carcinoma 256. Biochem Pharmacol 18 (1969) 1519-1527
99. Boland M.P., Knox R.J., and Roberts J.J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954(5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 41 (1991) 867-875
100. Knox R.J., Friedlos F., Jarman M., and Roberts J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37 (1988) 4661-4669
101. Searle P.F., Chen M.J., Hu L., et al. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol 31 (2004) 811-816
102. http://www.clinicaltrial.gov/
103. Patterson L.H., and McKeown S.R. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 83 (2000) 1589-1593
104. Hejmadi M.V., McKeown S.R., Friery O.P., McIntyre I.A., Patterson L.H., and Hirst D.G. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to toxic and hypoxic tumour cells. Br J Cancer 73 (1996) 499-505
105. McKeown S.R., Hejmadi M.V., McIntyre I.A., McAleer J.J., and Patterson L.H. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 72 (1995) 76-81
106. Patterson L.H., McKeown S.R., Ruparelia K., et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 82 (2000) 1984-1990
107. McKeown S.R., Friery O.P., McIntyre I.A., Hejmadi M.V., Patterson L.H., and Hirst D.G. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer 74 (1996) S39-S42
108. Friery O.P., Gallagher R., Murray M.M., et al. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer 82 (2000) 1469-1473
109. Gallagher R., Hughes C.M., Murray M.M., et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 85 (2001) 625-629 2002;87:1339
110. Loadman P.M., Swaine D.J., Bibby M.C., Welham K.J., and Patterson L.H. A preclinical pharmacokinetic study of the bioreductive drug AQ4N. Drug Metab Dispos 29 (2001) 422-426
111. Zeman E.M., Hirst V.K., Lemmon M.J., and Brown J.M. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12 (1988) 209-218
112. Brown J.M., and Lemmon M.J. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20 (1991) 457-461
113. Siim B.G., Menke D.R., Dorie M.J., and Brown J.M. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 57 (1997) 2922-2928
114. Holden S.A., Teicher B.A., Ara G., Herman T.S., and Coleman C.N. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84 (1992) 187-193
115. Dorie M.J., and Brown J.M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53 (1993) 4633-4636
116. Langmuir V.K., Rooker J.A., Osen M., Mendonca H.L., and Laderoute K.R. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54 (1994) 2845-2847
117. Lartigau E., and Guichard M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br J Cancer 73 (1996) 1480-1485
118. Dorie M.J., and Brown J.M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39 (1997) 361-366
119. Weitman S., Mangold G., Marty J., et al. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 43 (1999) 402-408
120. Emmenegger U., Morton G.C., Francia G., et al. Low dose metronomic daily cyclophosphamide and weekly tirapazamine: a well tolerated combination regimen with enhanced efficacy that exploits tumour hypoxia. Cancer Res 66 (2006) 1664-1674
121. Koch C.J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53 (1993) 3992-3997
122. Lunt S.J., Telfer B.A., Fitzmaurice R.J., Stratford I.J., and Williams K.J. Selective killing of hypoxic cells in primary tumours using tirapazamine reduces metastatic dissemination. Clin Cancer Res 11 (2005) 4212-4216
123. Kyle A.H., and Minchinton A.I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 43 (1999) 213-220
124. Hicks K.O., Pruijn F.B., Sturman J.R., Denny W.A., and Wilson W.R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 63 (2003) 5970-5977
125. Lopez de Cerain A., Marin A., Idoate M.A., Tunon M.T., and Bello J. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoural and normal tissues. Eur J Cancer 35 (1999) 320-324
126. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., and Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54 (1994) 1352-1354
127. Thomsen L.L., and Miles D.W. Role of nitric oxide in tumor progression: lessons from human tumors. Cancer Metastasis Rev 17 (1998) 107-118
128. Patterson L.H., and Murray G.I. Tumour cytochrome P450 and drug activation. Curr Pharm Des 8 (2002) 1335-1347
129. McKeown S.R., Ward C., and Robson T. Gene-directed enzyme prodrug therapy: a current assessment. Curr Opin Mol Ther 6 (2004) 421-435
130. Jounaidi Y., and Waxman D.J. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 60 (2000) 3761-3769
131. Cowen R.L., Williams K.J., Chinje E.C., et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64 (2004) 1396-1402
132. Patterson A.V., Williams K.J., Cowen R.L., et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 9 (2002) 946-954
133. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12 (1992) 5447-5454
134. Dachs G.U., Patterson A.V., Firth J.D., et al. Targeting gene expression to hypoxic tumor cells. Nat Med 3 (1997) 515-520
135. McErlane V., Yakkundi A., McCarthy H.O., et al. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med 7 (2005) 851-859
136. McCarthy H.O., Yakkundi A., McErlane V., et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther 10 (2003) 40-48
137. Yakkunndi A., McErlane V., Murray M., et al. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther 13 (2006) 598-605
138. Worthington J., Robson T., O'Keeffe M., and Hirst D.G. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther 9 (2002) 263-269
139. McNeish I.A., Green N.K., and Gilligan M.G. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 5 (1998) 1061-1069
140. Weedon S.J., Green N.K., McNeish I.A., et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer 86 (2000) 848-854
141. Palmer D.H., Mautner V., Mirza D., et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 22 (2004) 1546-1552
142. Lee D.J., Trotti A., Spencer S., et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 42 (1998) 811-815
143. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
144. Le Q.T., Taira A., Budenz S., et al. Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer 106 (2006) 1940-1949
145. Miller V.A., Ng K.K., Grant S.C., et al. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8 (1997) 1269-1271
146. Treat J., Johnson E., Langer C., et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16 (1998) 3524-3527
147. von Pawel J., von Roemeling R., Gatzemeier U., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18 (2000) 1351-1359
148. Reck M., von Pawel J., Nimmermann C., Groth G., and Gatzemeier U. Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC). Pneumologie 58 (2004) 845-849
149. Gatineau M., Rixe O., and Chevalier T.L. Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study. Clin Lung Cancer 6 (2005) 293-298
150. Williamson S.K., Crowley J.J., Lara Jr. P.N., et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23 (2005) 9097-9104
151. Bedikian A.Y., Legha S.S., Eton O., et al. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 8 (1997) 363-367
152. Bedikian A.Y., Legha S.S., Eton O., et al. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs 10 (1999) 735-739
153. Del Rowe J., Scott C., Werner-Wasik M., et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18 (2000) 1254-1259
154. Covens A., Blessing J., Bender D., Mannel R., and Morgan M. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100 (2006) 586-590
155. Maluf F.C., Leiser A.L., Aghajanian C., et al. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 16 (2006) 1165-1171
156. Smith H.O., Jiang C.S., Weiss G.R., et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 16 (2006) 298-305
157. Bengiat A., Steward W.P., Loadman P.M., Middleton D., and Talbot D. Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT) - first report. Proc Am Assoc Cancer Res (March 2004-March 2004). http://www.novacea.com/
158. Harris P.A., Dunk C.R., Albertella M.R., et al. Tumour specific activation of the hypoxic cell cytotoxin AQ4N: a phase I clinical study in solid tumours. Proc Am Assoc Cancer Res (2006)
159. Furman R.R., Bartlett N., Leonard J.P., et al. Banoxantrone (AQ4N), a tissue targeted prodrug: results of a phase 1 study in lymphomas. Proc Am Soc Hematol (2006)
160. Sarantopoulos J., Tolcher A., Wong A., et al. Banoxantrone (AQ4N): a phase 1 clinical trial of banoxantrone (AQ4N), a tissue CYP 450 targeted prodrug, in patients with advanced solid tumors. Proc Am Assoc Cancer Res (2006)
161. Doherty N., Hancock S.L., Kaye S., et al. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 29 (1994) 379-382
162. Senan S., Rampling R., Graham M.A., et al. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3 (1997) 31-38
163. Aghajanian C., Brown C., O'Flaherty C., et al. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 67 (1997) 127-130
164. Lara Jr. P.N., Frankel P., Mack P.C., et al. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a California cancer consortium phase I and molecular correlative study. Clin Cancer Res 9 (2003) 4356-4362
165. Hoff P.M., Saad E.D., Ravandi-Kashani F., Czerny E., and Pazdur R. Phase I trial of i.v. administered tirapazamine plus cyclophosphamide. Anticancer Drugs 12 (2001) 499-503
166. Rischin D. Hypoxia in head and neck cancer - Studies with hypoxic imaging and hypoxic cytotoxins. Proc ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium 2007.
167. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol 24 (2006) 2098-2104
168. Begleiter A. Clinical applications of quinone-containing alkylating agents. Front Biosci 5 (2000) E153-E171
169. Propper D.J., Levitt N.C., O'Byrne K., et al. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer 82 (2000) 1776-1782
170. Gadaleta C.D., Catino A., Ranieri G., Armenise F., Console G., and Mattioli V. Hypoxic stop-flow perfusion with mitomycin-C in the treatment of multifocal liver metastases. Usefulness of a vascular arterial stent to prevent iatrogenic lesions of the hepatic arterial wall. J Exp Clin Cancer Res 22 (2003) 203-206
171. van Ijken M.G., van Etten B., Guetens G., et al. Balloon catheter hypoxic abdominal perfusion with mitomycin C and melphalan for locally advanced pancreatic cancer: a phase I-II trial. Eur J Surg Oncol 30 (2004) 671-680
172. Haffty B.G., Wilson L.D., Son Y.H., et al. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 61 (2005) 119-128
173. Schellens J.H.M., Planting A.S.T., Van Acker B.A.C., et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 86 (1994) 906-912
174. McLeod H.L., Graham M.A., Aamdal S., Setanoians A., Groot Y., and Lund B. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. Eur J Cancer 32A (1996) 1518-1522
175. Dirix L.Y.F., Tonnesen J., Cassidy R., et al. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. Eur J Cancer 32A (1996) 2019-2022
176. Pavlidis N., Hanauske A.R., Gamucci T., et al. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 7 (1996) 529-531
177. Loadman P.M., Bibby M.C., and Phillips R.M. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 137 (2002) 701-709
178. Puri R., Palit V., Loadman P.M., et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol 176 (2006) 1344-1348
179. van der Heijden A.G., Moonen P.M., Cornel E.B., et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176 (2006) 1349-1353
180. Belkacemi Y., Tsoutsou P., Magne N., Castadot P., Azria D. Metabolic functional imaging for tumor radiosensitivity monitoring. Crit Rev Oncol Hematol 2007 [epub ahead of print].
181. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82 (2006) 699-757